Aquavit Pharmaceuticals, Inc. v. U-Bio Med, Inc.

District Court, S.D. New York·Decided April 17, 2020·No. 1:19-cv-03351·Unknown

Opinion

UNITED STATES DISTRICT COURT E DL OE CC #T :R ONIC ALLY FILED SOUTHERN DISTRICT OF NEW YORK DATE FILED: 04/17 /2020 ------------------------------------------------------------------- X : AQUAVIT PHARMACEUTICALS, INC., : : Plaintiff, : 19-CV-3351 (VEC) : -against- : MEMORANDUM : OPINION AND ORDER U-BIO MED, INC., GLOBAL MEDI PRODUCTS, : and NYUN SHI EUM aka NYON-SIK EUM, : : Defendants. : : ------------------------------------------------------------------- X VALERIE CAPRONI, United States District Judge: The parties each claim to be the rightful owners of trademarks related to an injection device marketed under the brand name Aquagold. While Plaintiff Aquavit Pharmaceuticals, Inc. (“Aquavit”) registered those trademarks in the United States and Korea, Defendants U-Bio Med, Inc. and Nyun Shi Eum1 (“Defendants”) registered identical or virtually identical marks in the European Union and certain other jurisdictions. The Court issued a modified preliminary injunction that prohibits Defendants from using the marks except in the countries in which Defendants own the relevant rights; Defendants also cannot use the marks in foreign jurisdictions in a way that is likely to affect commerce in the United States. Modified Preliminary Injunction (“MPI”) (Dkt. 65) § 1.P. Thereafter, Plaintiff claimed that Defendants were not in compliance with the MPI, and the Court referred the contempt motion to Magistrate Judge Robert Lehrburger for a hearing and a report and recommendation. Judge Lehrburger concluded that Defendants have not substantially complied with the MPI and that attorney’s fees and costs, in an 1 Defendant Global Medi Products has not appeared in this action or otherwise responded to the Complaint. amount to be determined, should be awarded to Plaintiff as a sanction. Defendants have objected to virtually every one of Judge Lehrburger’s findings and recommendations. For the reasons set forth below, the Court concludes that a finding of civil contempt is warranted and that a partial award of fees and costs is appropriate.

I. BACKGROUND The Court assumes familiarity with the parties’ underlying dispute, which is described in this Court’s opinion denying Defendants’ motion to dismiss. See Aquavit Pharmaceuticals, Inc. v. U-Bio Med, Inc., No. 19-CV-3351, 2020 WL 832249, at *1–2 (S.D.N.Y. Feb. 19, 2020). The recitation below is limited to the facts and procedural history needed to contextualize Plaintiff’s contempt motion. A. The Preliminary Injunction On April 15, 2019, Plaintiff commenced this action by seeking a temporary restraining order (TRO) prohibiting Defendants from, among other things, using or imitating Plaintiff’s trademarks, which are registered in the United States and South Korea and used in the marketing

of microinjection devices. Order to Show Cause for Preliminary Injunction and Temporary Restraining Order (“OTSC”) (Dkt. 3); Seaton Decl. (Dkt. 15) ¶ 3. Those trademarks include AQUAGOLD, FINE TOUCH, MICROCHANNEL TECHNOLOGY, and AQUAVIT PHARMCEUTICALS (“Marks” or “Aquagold marks”). OTSC § I.A.1. The Court granted the TRO and ordered Defendants to show cause at a hearing on April 19, 2019, why a preliminary injunction should not issue. OTSC at 1. Defendants failed to appear at the hearing, and the TRO was converted to a preliminary injunction. Preliminary Injunction (“PI”) (Dkt. 19). On May 10, 2019, Defendants appeared and filed a motion to dismiss the complaint and dissolve the injunction. Dkt. 32. The Court held a hearing and found no basis to dissolve the PI but permitted Defendants to file a motion to modify its scope. See Dkt. 55 at 39. At the same time, Plaintiff contended at the hearing that Defendants had violated the TRO and PI; the Court

noted that the proper remedy was to move for contempt. Dkt. 55 at 35–36. A week later, Defendants moved to narrow the scope of the PI. See Dkt. 47. While the motion for modification was pending, Plaintiff moved to hold Defendants in contempt for failing to comply with the original injunction. Dkts. 49–51. Defendants allegedly continued to use the Marks after receiving notice of the PI; Defendants went so far as to use the Marks to drum up sales for the express purpose of fundraising to defend this litigation. Dkt. 50-1 at 2. On June 21, 2019, the Court issued a modified preliminary injunction as to Defendants— the original injunction remains in effect as to Global Medi Products, which defaulted and did not join in the motion for modification. MPI (Dkt. 65) at 6. The Court recognized that Defendants

owned the relevant trademarks in the EU and ruled that the injunction does not forbid their use of the EU marks, as long as such use does not confuse American consumers or violate Plaintiff’s rights under the Lanham Act. MPI at 4. To accommodate this unusual situation of geographically splintered intellectual property rights, the Court exempted from the scope of the injunction Defendants’ use of Aquagold marks in countries in which they hold the relevant rights, provided that certain conditions designed to protect Plaintiff’s rights are met. MPI at 3– 5; see Sterling Drug, Inc. v. Bayer AG, 14 F.3d 733, 747 (2d Cir. 1994) (instructing district courts to carefully balance rights of concurrent trademark holders). Specifically, the MPI stated that: U-Bio Med, Inc. and Nyun Shi Eum are not enjoined from using in commerce any “Aquagold” marks legally owned by U-Bio Med, Inc. and Nyun Shi Eum, provided that: (1) any use of such mark is restricted to products sold in the commerce of the country or countries in which the relevant mark is registered to U-Bio Med, Inc. and Nyun Shi Eum, (2) any use of such mark must be accompanied by a reasonably visible disclaimer, translated into English, Korean, and the native language of the country in which the mark is used in commerce, indicating that Defendants’ “Aquagold” microinjection device is designed and manufactured by a different company than the company that designs and manufactures “Aquagold” devices sold in the United States and Korea and that Defendants’ devices may perform differently than “Aquagold” devices sold in the United States and Korea (“Disclaimer”), (3) any use of such mark on a product must include the Disclaimer on both the product packaging and any user instructions, (4) any use of such mark must not be accompanied by any American or Korean national flags or symbols, American or Korean registration or serial numbers, or any other references that associate Defendants’ product with Plaintiff’s American or Korean trademarks, and (5) the sale or promotion of such products must not be accompanied by any comparison to Plaintiff’s devices, including any disparagement of Plaintiff’s devices as inferior or counterfeit. MPI § 1.P. In other words, to continue using Aquagold marks in countries in which Defendants have registered the marks, Defendants must include, on their devices and marketing materials, a disclaimer distinguishing their product from Plaintiff’s device; Defendants also must not otherwise disparage or compare their product to Plaintiff’s or attempt to profit from Plaintiff’s goodwill in the United States and Korea. Id. On July 11, 2019, after giving Defendants significant time to comply with the terms of the MPI, the Court granted Plaintiff’s earlier request for an order directing Defendants to show cause why they should not be held in contempt. Dkt. 84. In that order, the Court directed both Plaintiff and Defendants to address in their papers whether any non-compliance identified in the original motion had since been cured or rendered moot by the MPI. Id. at 6. Before briefing on the contempt motion could be completed, Plaintiff’s now-former counsel filed a motion to withdraw from representation due to a breakdown in the attorney-client relationship. See Dkts. 96, 100.

Free access — add to your briefcase to read the full text and ask questions with AI

Aquavit Pharmaceuticals, Inc. v. U-Bio Med, Inc., (S.D.N.Y. 2020).

Aquavit Pharmaceuticals, Inc. v. U-Bio Med, Inc. (Aquavit Pharmaceuticals, Inc. v. U-Bio Med, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

United States v. Rylander
460 U.S. 752 (Supreme Court, 1983)
United States v. Male Juvenile (95-Cr-1074)
121 F.3d 34 (Second Circuit, 1997)
John B. Stetson Co. v. Stephen L. Stetson Co.
128 F.2d 981 (Second Circuit, 1942)
Bowens v. Atlantic Maintenance Corp.
546 F. Supp. 2d 55 (E.D. New York, 2008)
Powell v. Ward
487 F. Supp. 917 (S.D. New York, 1980)
Wilds v. United Parcel Service, Inc.
262 F. Supp. 2d 163 (S.D. New York, 2003)
National Research Bureau, Inc. v. Kucker
481 F. Supp. 612 (S.D. New York, 1979)
CBS Broadcasting Inc. v. FilmOn.com, Inc.
814 F.3d 91 (Second Circuit, 2016)
Sterling Drug, Inc. v. Bayer AG
14 F.3d 733 (Second Circuit, 1994)
Pineda v. Masonry Construction, Inc.
831 F. Supp. 2d 666 (S.D. New York, 2011)